Searched for
PHARMACEUTICAL MANUFACTURING COMPLIANCE
USFDA ends inspection of Aurobindo Pharma arm's facility with 4 observationsAurobindo Pharma announced its subsidiary Lannett Company LLC's facility inspection concluded. The US Food and Drug Administration conducte...- Symbiotec Pharmalab’s Rs 1,757 crore IPO opens with GMP hinting at 41% upside. Should you bid?Symbiotec Pharmalab IPO GMP: Symbiotec Pharmalab’s Rs 1,757 crore IPO opened August 24, with a Rs 938–988 price band and 41% grey-market pr...
- India gets nearly Rs 5,000 crore FDI after easing rules for Chinese-linked firmsNew foreign investment rules are yielding positive results for India's economy. Twenty-nine investment proposals totaling over Rs 4,895 cro...
- Strikes in the Gulf changing rules behind India’s big-money betsIndia Private Equity Investment 2026: Geopolitical risks now shape private equity deal considerations in India. Investors increasingly focu...
- Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health SciencesPharmaceuticals giant Cipla announced its merger with Inzpera Healthsciences Limited on Wednesday. This consolidation aims for more efficie...
- Symbiotec Pharmalab sets price band for Rs 1,757 crore IPO, to open on August 24Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 1...
- India's pharma sector must shift from cost competitiveness to innovation, global quality: ExpertsFor the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that inc...
- Aurobindo Pharma arm Eugia Pharma's Telangana unit gets warning letter from USFDAAurobindo Pharma announced its subsidiary Eugia Pharma received a USFDA warning letter. This follows an inspection of their Telangana formu...
- 'You are using sword to kill mosquito': Bombay HC tells Tukaram Mundhe-led FDA to use power judiciouslyThe Bombay High Court has told the Tukaram Mundhe-led Maharashtra FDA to use its powers judiciously after Cadila Pharmaceuticals challenged...
- Govt tightens drug quality net, initiates 950 actions since 2022: Over 1,100 cough syrup makers facing intensive audits amid quality concernsThe government has initiated 950 enforcement actions against pharmaceutical companies since December 2022. These actions aim to improve the...
- Maharashtra FDA cracks down on Ayurvedic drug makers, cancels 10 licencesMaharashtra FDA has launched a statewide crackdown on Ayurvedic drug manufacturers. Inspections revealed serious violations of manufacturin...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- India's big billion-dollar trade deals are done. Now comes the real testIndia has spent years negotiating free trade agreements with some of the world's biggest economies. But signing the deals was only half the...
- Saudi Aramco supplier HD Fire plans to launch IPO in OctoberFire protection systems manufacturer HD Fire Protect is planning to launch its IPO in October through an offer for sale of 2.6 crore shares...
- Trade deals open new markets for Indian medical device makers, but import risks remain: AiMeDThe EU offers the biggest long-term opportunity for Indian medical device makers, while the UK has more immediate strategic value, says AiM...
- FSSAI suspends Kolkata bakery major Switz Foods' licence over unhygienic manufacturing, pest infestationIndia's food regulator has suspended Switz Foods' manufacturing licence. Serious non-compliances were found during a recent unit inspection...
- Maharashtra FDA trains guns on overpriced drugsMaharashtra FDA plans to approach the NPPA regarding exorbitant drug prices. The agency is examining data and will take action against unet...
- India takes action against 90% of inspected high-risk pharmaceutical facilities, regulator saysAmid increasing global concerns over Indian pharmaceuticals, India's drug regulator is rigorously addressing high-risk manufacturing sites....
- FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plantThe FSSAI has suspended Dior Pharmaceuticals' license due to serious violations. The nutraceutical factory operated with severely deficient...
- Gujarat industry seeks easier access to incentives, lower cost of doing businessIndustry stakeholders say the opportunity for them lies in strengthening the link between its large industrial base and MSMEs while reducin...
Load More
